+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
ID06436534

Study of Ganciclovir Capsules for Treating Moderate-to-Severe Refractory Allergic Rhinitis Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2026-07-13

50

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the effects of ganciclovir capsules on patients with refractory moderate-to-severe allergic rhinitis. This study aims to evaluate whether ganciclovir improves nasal symptoms and quality of life, as well as to assess its safety. The research is a randomized, double-blind, placebo-controlled clinical trial conducted at a single center. Participants will be randomly assigned to receive either ganciclovir capsules or placebo capsules for two weeks, alongside daily mometasone furoate nasal spray. The study includes a screening phase, a 14-day treatment phase, and a two-week follow-up phase. During screening, various tests and symptom assessments are conducted to confirm eligibility. The treatment phase involves taking oral capsules twice daily and continuing nasal spray use. Throughout the trial, participants will have nasal symptom scores, nasal secretions, blood samples, and safety tests such as vital signs and liver and kidney function monitored. Researchers will compare changes in symptom scores and quality of life measures from baseline to the end of treatment and follow-up. The overall participation lasts about six weeks, including screening, treatment, and follow-up.

CONDITIONS

Brief Title

Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis

Research Team

J

Jianjun Chen

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here